The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arndt, P. G.
Right arrow Articles by Worthen, G. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arndt, P. G.
Right arrow Articles by Worthen, G. S.
The Journal of Immunology, 2006, 177: 7233-7241.
Copyright © 2006 by The American Association of Immunologists, Inc.

Systemic Inhibition of the Angiotensin-Converting Enzyme Limits Lipopolysaccharide-Induced Lung Neutrophil Recruitment through Both Bradykinin and Angiotensin II-Regulated Pathways1

Patrick G. Arndt2,*, Scott K. Young{dagger}, Katie R. Poch{dagger}, Jerry A. Nick*,{dagger}, Sandor Falk{ddagger}, Robert W. Schrier{ddagger} and G. Scott Worthen*,{dagger}

* Division of Pulmonary and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, CO; {dagger} Department of Medicine, National Jewish Medical and Research Center, Denver, CO; and {ddagger} Division of Renal Diseases and Hypertension, University of Colorado Health Sciences Center, Denver, CO


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Recruitment of neutrophils to the lung is a sentinel event in acute lung inflammation. Identifying mechanisms that regulate neutrophil recruitment to the lung may result in strategies to limit lung damage and improve clinical outcomes. Recently, the renin angiotensin system (RAS) has been shown to regulate neutrophil influx in acute inflammatory models of cardiac, neurologic, and gastrointestinal disease. As a role for the RAS in LPS-induced acute lung inflammation has not been described, we undertook this study to examine the possibility that the RAS regulates neutrophil recruitment to the lung after LPS exposure. Pretreatment of mice with the angiotensin-converting enzyme (ACE) inhibitor enalapril, but not the anti-hypertensive hydralazine, decreased pulmonary neutrophil recruitment after exposure to LPS. We hypothesize that inhibition of LPS-induced neutrophil accumulation to the lung with enalapril occurred through both an increase in bradykinin, and a decrease in angiotensin II (ATII), mediated signaling. Bradykinin receptor blockade reversed the inhibitory effect of enalapril on neutrophil recruitment. Similarly, pretreatment with bradykinin receptor agonists inhibited IL-8-induced neutrophil chemotaxis and LPS-induced neutrophil recruitment to the lung. Inhibition of ATII-mediated signaling, with the ATII receptor 1a inhibitor losartan, decreased LPS-induced pulmonary neutrophil recruitment, and this was suggested to occur through decreased PAI-1 levels. LPS-induced PAI-1 levels were diminished in animals pretreated with losartan and in those deficient for the ATII receptor 1a. Taken together, these results suggest that ACE regulates LPS-induced pulmonary neutrophil recruitment via modulation of both bradykinin- and ATII-mediated pathways, each regulating neutrophil recruitment by separate, but distinct, mechanisms.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
A role for the renin angiotensin system (RAS)3 in cardiovascular disease has been well established, with inhibition of the angiotensin-converting enzyme (ACE) decreasing the incidence of recurrent myocardial infarction, the development of congestive heart failure, and death (1, 2, 3, 4, 5, 6). Although less well characterized, several studies have also suggested a role for the RAS in pulmonary disease. Levels of ACE are elevated in bronchoalveolar lavage fluid (BALF) from subjects with sarcoidosis (7), idiopathic pulmonary fibrosis (7), and the acute respiratory distress syndrome (ARDS) (8), with mortality from ARDS positively correlated with ACE levels (9). Finally, the incidence and severity of pneumonia is decreased in subjects on ACE inhibitors (ACE-I) (10, 11, 12). Taken together, these studies suggest that ACE activity may regulate the acute inflammatory response in the lung, and in particular acute inflammation after exposure to LPS.

Although improvements in hemodynamics (i.e., blood pressure and cardiac output) are undoubtedly important mechanisms underlying the positive outcomes in subjects with cardiovascular disease treated with ACE-I, other mechanisms have also been proposed. For example, ACE has been suggested to regulate acute inflammation, as evidenced by the decrease in acute inflammation, and specifically cardiac neutrophil influx, with ACE inhibitor pretreatment in models of viral myocarditis (13, 14, 15) and cardiac ischemia/reperfusion (16), respectively. Similar findings have also been reported in noncardiovascular disease models, wherein inhibition of the RAS decreased localized neutrophil recruitment after intestinal or cerebral ischemia/reperfusion (17, 18), in a model of gastric ulceration (19), and in several models of pulmonary disease (20, 21, 22, 23, 24). Specifically in the lung, inhibition of ACE decreased the acute cellular inflammatory response in a bleomycin-induced model of interstitial lung disease (20), whereas inhibition of angiotensin II (ATII) decreased pulmonary neutrophil recruitment after the intratracheal administration of fMLP, Pseudomonas aeruginosa, or Bordetella bronchiseptica (21, 22). Although modulation of the RAS has been shown to decrease inflammation in the lung after exposure to formylated bacterial peptides or bacterial organisms, a role for ACE in acute lung inflammation induced by LPS and the mechanisms regulating the inhibition of pulmonary neutrophil recruitment with RAS modulation have not been examined previously.

The direct effect of ACE is to increase levels of ATII and decreases levels of bradykinin. Thus in the setting of ACE inhibition, regulation of neutrophil recruitment may occur as a result of a decrease in ATII, or an increase in bradykinin-induced signaling. Blockade of ATII decreased neutrophil influx after intratracheal challenge by Pseudomonas aeruginosa and Bordetella bronchiseptica, thereby suggesting that ATII induces neutrophil recruitment and is proinflammatory (21, 22). In contrast, the role of bradykinin in regulating pulmonary neutrophil recruitment appears to be more complex, with bradykinin reported to be either pro- or anti-inflammatory depending on the stimulus and animal model used (25, 26, 27, 28, 29, 30). More importantly, although modulation of ATII or bradykinin-induced signaling has been reported to modify neutrophil recruitment, the specific mechanism(s) by which this occurs is not clearly defined. One proposed mechanism is through a decrease in neutrophil capillary retention or adhesion, via decreases in CD11b or L-selectin expression (16, 17, 18). Alternatively, inhibition of ACE may modulate neutrophil recruitment via the regulation of plasminogen activator inhibitor-1 (PAI-1) expression. We have recently shown that PAI-1 regulates pulmonary neutrophil recruitment in a model of LPS-induced acute lung inflammation (31), and although not previously examined in the lung, inhibition of ACE has been shown to diminish PAI-1 expression (32, 33, 34, 35, 36, 37, 38, 39), with this diminution likely mediated through a decrease in the levels of ATII, as signaling through ATII is known to up-regulate PAI-1 expression in vitro and in vivo (40, 41, 42, 43, 44, 45, 46, 47).

We undertook the present study to examine the role of the RAS in LPS-induced acute lung inflammation and to examine the mechanisms by which modulation of the RAS regulates neutrophil recruitment to the lung after exposure to LPS. Herein, we show that ACE inhibition decreased neutrophil recruitment to the lung after LPS exposure with an increase in bradykinin-, and a decrease in ATII-, induced signaling proposed as mechanisms for this diminution. Augmentation of bradykinin mediated signaling inhibited neutrophil chemotaxis whereas inhibition of ATII-mediated signaling decreased PAI-1 expression, thereby limiting neutrophil recruitment to the lung after exposure to LPS.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Animals

Female C57BL/6 mice, or ATII type 1a receptor knockout (ATIaR–/–) (on a B6129P2 background), age 8–12 wk, were obtained from The Jackson Laboratory. Animals were maintained in a pathogen-free environment on a 12-h light/dark cycle with full access to food and water. All animal protocols were approved by the Animal Care and Use Committee at National Jewish Medical and Research Center.

Materials

All materials used are endotoxin free with routine testing performed for the presence of endotoxin by the Limulus amebocyte lysate test (Pyrogent; Cambrex). LPS (Escherichia coli, 0111:B4), enalapril, hydralazine, the bradykinin B1 receptor agonist [Lys-des-Arg9]-bradykinin, the bradykinin B2 receptor agonist [Hyp3]-bradykinin, and the bradykinin B1 receptor antagonist [des-Arg10]-HOE 140 were obtained from Sigma-Aldrich. The bradykinin B2 receptor antagonist HOE 140 was obtained from BIOMOL, losartan was obtained from Cayman Chemical, and IL-8 was obtained from R&D Systems. Hydroxypropylmethylcellulose was obtained from Fisher Scientific. Recombinant constitutively active PAI-1 (MPAI-191L) was obtained from Molecular Innovations, and calcein-AM was obtained from Molecular Probes.

Animal manipulation

ACE inhibition. To examine the role of ACE in LPS-induced lung inflammation, mice were pretreated with enalapril (10 mg/kg, dissolved in 100 µl of hydroxypropylmethylcellulose), or hydroxypropylmethylcellulose as control, by oral gavage once daily for 1 or 6 days, with an additional dose given 5 h before LPS exposure. Mice were exposed to aerosolized LPS (300 µg/ml in 0.9% saline) for 20 min as described previously (48, 49, 50). In selected experiments, as a control for the hemodynamic effects of enalapril, separate groups of mice were pretreated with hydralazine (10 or 50 mg/kg, dissolved in 100 µl of hydroxypropylmethylcellulose), once daily for 6 days with a final dose given 5 h before LPS exposure. To determine whether post-LPS ACE inhibition limits pulmonary neutrophil influx, separate experiments were designed in which mice were administered enalapril (10 mg/kg) 1 h after exposure to LPS.

At set points after LPS exposure, mice were sacrificed by exsanguination, with blood collected, bronchoalveolar lavage (BAL) performed, and lungs isolated, as described previously (48, 49). To determine the number of neutrophils recruited to the alveolar space, total BAL cell counts were assessed by hemocytometer with cell differential counts obtained from cytocentrifuged BAL samples. After isolation, lungs were snap frozen in dry ice and stored at –70°C. Collected blood was placed in buffer (HEPES 50 mM (pH 7.6), NaCl 100 mM, EDTA 2 mM, sodium pyrophosphate 5 mM, sodium orthovanadate 1 mM, and Triton X-100 1%) then centrifuged at 10,000 rpm for 5 min with the supernatant frozen at –20°C.

ATII 1a receptor inhibition. The ATII 1a receptor inhibitor losartan (10 mg/kg, oral gavage), or hydroxypropylmethylcellulose as control, was administered daily to C57BL/6 mice for 3 days with a final dose given 5 h before aerosolized LPS exposure. Four or 24 h after exposure to LPS, mice were sacrificed with blood collected, BAL performed, and lungs isolated as described above.

Invasive blood pressure measurement. Mice were anesthetized with sodium pentobarbital (60 mg/kg) and placed on a thermostatically controlled surgical table. The carotid artery was isolated and then cannulated using custom pulled tubing (PE250). The catheter was then connected to a TransPac IV disposable transducer (Abbott Critical Care Systems) via a three-way stop-cock with the transducer connected to a Transonic Systems model T106 small animal blood flow meter. The pressure wave form was analyzed using WinDaq Waveform recording software (Dataq Instruments). Mean arterial pressure was calculated using the formula: mean arterial pressure = (2/3 diastolic blood pressure) + (1/3 systolic blood pressure) and is expressed in mmHg.

Role of bradykinin in LPS-induced acute lung inflammation. C57BL/6 mice were pretreated with enalapril (10 mg/kg) for 6 days, as above, then administered the bradykinin B2 receptor antagonist HOE 140 (100 µg/kg, i.p.) or the bradykinin B1 receptor antagonist [des-Arg10]-HOE 140 (100 µg/kg, i.p.) 1 h before exposure to LPS, with animals sacrificed 4 or 24 h after LPS exposure. In separate experiments, mice were pretreated with the bradykinin receptor 1 agonist [Lys-des-Arg9]-bradykinin (100 µg/kg, i.v.) or the bradykinin receptor 2 agonist [Hyp3]-bradykinin (100 µg/kg, i.v.) 20 min before exposure to aerosolized LPS (as above). Animals were sacrificed 4 h after LPS exposure with the recruitment of neutrophils to the alveolar space assessed.

PAI-1 repletion. To assess the role of PAI-1 in the inhibition of LPS-induced pulmonary neutrophil recruitment by systemic ACE inhibition, constitutively active PAI-1 (10 or 50 µg/mouse), or PBS as control, was administered intratracheally to enalapril pretreated mice (6 day pretreatment, as above), followed by exposure to aerosolized LPS and sacrifice 4 h after LPS exposure.

Myeloperoxidase (MPO) assay. As a marker of pulmonary neutrophil recruitment to the lung parenchyma, MPO levels were assessed from harvested lung as described previously (48).

Chemotaxis. Neutrophil chemotaxis to IL-8 was assessed using modified Boyden chambers. Isolated human neutrophils (1 x 106) were labeled with calcein-AM (1 ng/ml) for 10 min at 37°C, washed once in Kreb’s Ringers phosphate with dextrose (KRP-D), and then resuspended in KRP-D. Neutrophils were incubated with [Hyp3]-bradykinin (0.1–100 µM), or KRP-D as control, at 37°C for 30 min and then placed into the upper wells of modified Boyden chambers. IL-8 (50 ng/ml) or KRP-D was placed into the lower wells with neutrophil chemotaxis, and nondirectional movement was assessed by measuring fluorescence (excitation wavelength 485, emission wavelength 528) in the lower chamber every 2 min over a 60-min time span using a fluorescent plate reader (FLX800; BioTek Instruments).

ELISA. Levels of KC, MIP-2, and PAI-1 were assessed in BALF or lung homogenates using commercially available ELISA kits as described previously (31). Specifically for PAI-1, ELISA plates were obtained from Molecular Innovations, which specifically detect total PAI-1 or active PAI-1 only with assays performed per the manufacturer’s recommendations. Lung homogenates were prepared by homogenizing previously frozen lung tissue in PBS with 0.1% Triton X-100 supplemented with PMSF (300 mM), aprotinin (10 µg/ml), and leupeptin (10 µg/ml). Homogenates were then centrifuged at 5000 rpm for 10 min with supernatants collected and frozen at –20°C until used in the assays.

Statistics. Statistical analysis was performed by one way ANOVA with Tukey-Kramer post hoc analysis or Student’s t test as indicated using Prism software (GraphPad Software). All graphs are presented as means ± SEM. A p value of <0.05 was considered significant.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
Systemic inhibition of ACE decreases pulmonary neutrophil recruitment after exposure to LPS

To examine a role for the RAS, and in particular ACE, in LPS-induced acute lung inflammation, C57BL/6 mice were administered enalapril (10 mg/kg, oral gavage) daily for 1 or 6 days, exposed to aerosolized LPS (300 µg/ml, 20 min), with neutrophil recruitment to the lung assessed at 4 or 24 h after LPS exposure. Pretreatment with enalapril decreased neutrophil recruitment to the alveolar space at both the 4 and 24 h post-LPS time points with more robust inhibition seen at 4 h (Fig. 1A). In addition, pretreatment with enalapril for 6 days, compared with a single day, was associated with a greater diminution in LPS-induced neutrophil recruitment to the alveolar compartment (Fig. 1A). Similar to the recruitment of neutrophils to the alveolar compartment, neutrophil recruitment to the lung, as assessed by MPO levels, was decreased in mice pretreated with enalapril for 6 days and then exposed to LPS compared with those exposed to LPS alone (Fig. 1B). In contrast, a single day of enalapril pretreatment was not effective in decreasing the LPS-induced recruitment of neutrophils to the lung, as assessed by MPO, compared with mice exposed to LPS alone (Fig. 1B). To exclude the possibility that the inhibitory effect of enalapril on LPS-induced pulmonary neutrophil recruitment was due to a decrease in systemic blood pressure, the antihypertensive agent hydralazine was used as a control. Mice were administered enalapril (10 mg/kg) or hydralazine (10 or 50 mg/kg) daily for 6 days, exposed to LPS, with pulmonary neutrophil recruitment assessed 4 h after exposure to LPS. Pretreatment with hydralazine, in contrast to enalapril, did not diminish neutrophil recruitment to the alveolar space at either dose (Fig. 1C, left). To examine whether pretreatment with enalapril or hydralazine had similar effects on blood pressure, mice were pretreated with enalapril (10 mg/kg) or hydralazine (50 mg/kg) for 6 days with blood pressure measured by carotid artery cannulization at the end of the 6 day pretreatment. Pretreatment with either enalapril or hydralazine decreased blood pressure to a similar extent compared with animals treated with PBS only (Fig. 1C, right). Finally, to determine whether inhibition of ACE after LPS exposure is also effective in diminishing neutrophil recruitment to the lung, mice were exposed to LPS then treated with a single dose of enalapril (10 mg/kg) 1 h after LPS exposure. Postexposure treatment with enalapril decreased LPS-induced neutrophil recruitment to the alveolar space at 4 h but was ineffective at the later time point (Fig. 1D).


Figure 1
View larger version (18K):
[in this window]
[in a new window]

  		FIGURE 1. Enalapril diminishes neutrophil recruitment to the lung after exposure to LPS. A and B, Female C57BL/6 mice (n = 5) were pretreated with enalapril (10 mg/kg, orally) for 1 or 6 days and then exposed to aerosolized LPS (300 µg/ml; 20 min) with neutrophil recruitment to the alveolar space determined at 4 or 24 h and to the lung, as assessed by MPO, at 4 h post-LPS performed as described previously (48 49 ). (C) unmanipulated controls and (E) enalapril pretreated only. *, p < 0.001 L vs L+E 6 day 4 and 24 h and 1 day 4 h, #, p < 0.05 L vs L+E 1 day 24 h, **, p < 0.01 L vs L+E. C, Left, Female C57BL/6 mice (n = 5) were pretreated with enalapril (10 mg/kg, orally) or hydralazine (10 or 50 mg/kg; orally) for 6 days, exposed to LPS, with neutrophil recruitment to the alveolar space assessed. *, p < 0.001 L vs L+E. Right, Mice were exposed to enalapril (Enal) or hydralazine (Hydral), or PBS as control (C), for 6 days, as above, and invasive blood pressure was measured as per Materials and Methods with mean blood pressures calculated. #, p < 0.001 Enal vs C and Hydral vs C. D, Mice were exposed to aerosolized LPS, as above, then administered enalapril (10 mg/kg), 1 h after exposure to LPS. Neutrophil recruitment to the alveolar space was assessed at 4 or 24 h after LPS exposure. *, p < 0.05 L vs L+E.

 
Systemic inhibition of ACE decreases pulmonary neutrophil recruitment via modulation of both bradykinin and ATII-induced signaling

As ACE inhibition increases bradykinin and decreasing ATII levels, we tested the effect of modulation of signaling by bradykinin or ATII as potential mechanisms for the effect of enalapril treatment on lung inflammation. To assess the role of bradykinin in our model, C57BL/6 mice were administered i.v. the bradykinin B1 receptor agonist [Lys-des-Arg9]-bradykinin (100 µg/kg), the bradykinin B2 receptor agonist [Hyp]-bradykinin (100 µg/kg), or PBS as control 20 min before exposure to LPS. Pretreatment with the B1 or B2 receptor agonist significantly decreased neutrophil recruitment to the lung at both the 4-h (Fig. 2A) and 24-h (data not shown) time points, with similar inhibition by either the B1 or B2 receptor agonist (Fig. 2A). As this suggested that bradykinin-induced signaling regulates pulmonary neutrophil recruitment after exposure to LPS, we next assessed whether an increase in bradykinin-induced signaling is a mechanism for the decrease in LPS-induced pulmonary neutrophil recruitment with enalapril pretreatment in our model. To determine this, we used specific inhibitors toward the bradykinin B1 and B2 receptors. To mice pretreated for 6 days with enalapril, the B1 receptor antagonist [des-Arg10]-HOE 140 (100 µg/kg, i.p.), the B2 receptor antagonist HOE 140 (100 µg/kg, i.p.), or both were administered 1 h before LPS exposure. Administration of either the B1 or B2 receptor antagonist reversed the inhibition of pulmonary neutrophil recruitment in the setting of systemic ACE inhibition at both the 4-h (Fig. 2B) and 24-h (data not shown) time points.


Figure 2
View larger version (12K):
[in this window]
[in a new window]

  		FIGURE 2. Bradykinin- and ATII-mediated signaling regulate neutrophil recruitment to the lung after exposure to LPS with antagonism of bradykinin-induced signaling reversing the inhibitory effect of enalapril. A, C57BL/6 mice (n = 5) were administered the bradykinin receptor 1 agonist [Lys-des-Arg9]-bradykinin (100 µg/kg, i.v.) or the bradykinin receptor 2 agonist [Hyp3]-bradykinin (100 µg/kg, i.v.) 20 min before exposure to aerosolized LPS. Neutrophil recruitment to the alveolar space was determined 5 h after LPS exposure as described above. *, p < 0.001 LPS vs LPS+B1 and LPS vs LPS+B2. B, To mice (C57BL/6) (n = 5) pretreated with enalapril (10 mg/kg; 6 days) was administered the bradykinin B1 receptor antagonist [des-Arg10]-HOE 140 (100 µg/kg, i.p.) (B1) or the bradykinin B2 receptor antagonist HOE 140 (100 µg/kg, i.p.) (B2) 1 h before exposure to LPS. Neutrophil accumulation in the alveolar space was assessed 4 h after exposure to LPS. *, p < 0.01 LPS vs LPS plus enalapril. C, C57BL/6 mice were administered losartan (10 mg/kg), or hydroxypropylmethylcellulose as control, orally for 3 days and then exposed to LPS. Neutrophil accumulation in the alveolar space was assessed 4 and 24 h after exposure to LPS. *, p < 0.05 LPS+Los vs LPS; #, p < 0.001 LPS+Los vs LPS.

 
Next, we determined whether ATII-induced signaling regulates neutrophil recruitment to the lung after exposure to LPS. Mice were pretreated for 3 days with the ATII 1a receptor antagonist losartan (10 mg/kg), or hydroxypropylmethylcellulose as control, exposed to LPS with neutrophil recruitment to the alveolar space assessed at 4- and 24-h post-LPS exposure. Pretreatment with losartan decreased LPS-induced neutrophil recruitment at both the 4- and 24-h time points, with a more significant diminution at the later post-LPS time point (Fig. 2C).

A decrease in neutrophil chemoattractants is not a mechanism for the diminution in neutrophil recruitment in the setting of systemic ACE inhibition

To determine whether a decrease in the level of the murine neutrophil chemoattractant chemokines KC or MIP-2 was a mechanism for the decrease in pulmonary neutrophil recruitment in the setting of systemic ACE inhibition, we examined their levels in BALF. Compared with animals exposed to LPS only, there was no decrease in the levels of KC and MIP-2 in animals pretreated with enalapril and then exposed to LPS compared with those exposed to LPS alone (Fig. 3).


Figure 3
View larger version (11K):
[in this window]
[in a new window]

  		FIGURE 3. Enalapril pretreatment does not diminish levels of the neutrophil chemoattractants in the alveolar space after exposure to LPS. Levels of KC and MIP-2 were measured by ELISA from 4 h post-LPS BALF of mice pretreated with enalapril (10 mg/kg; 6 days) and exposed to LPS (L+E) or exposed to LPS (L) alone.

 
Pre-exposure of neutrophils to bradykinin decreases neutrophil chemotaxis

To determine a mechanism by which bradykinin-induced signaling decreased neutrophil recruitment to the lung after exposure to LPS we examined chemotaxis. Although systemic inhibition of ACE did not decrease the level of neutrophil chemoattractants after exposure to LPS (Fig. 3), the ability of neutrophils to respond functionally to these chemokines may be impaired in the setting of systemic ACE inhibition, with an augmented exposure of neutrophils to bradykinin as one possible mechanism. To examine this possibility, human neutrophils were pretreated with the B2 receptor agonist [Hyp3]-bradykinin (0.1–100 µM), or KRP-D as control, followed by the assessment of neutrophil chemotaxis to IL-8 (see Materials and Methods). Pre-exposure of neutrophils to [Hyp3]-bradykinin decreased their subsequent chemotaxis toward IL-8 in a dose-dependent manner (Fig. 4A). In contrast, pretreatment of neutrophils with [Hyp3]-bradykinin had no effect on the nondirectional movement (chemokinesis) of neutrophils at any concentration (Fig. 4B and data not shown).


Figure 4
View larger version (23K):
[in this window]
[in a new window]

  		FIGURE 4. Pre-exposure of neutrophils to bradykinin inhibits IL-8-induced chemotaxis but not the nondirectional movement of neutrophils. Human neutrophils (1 x 106)(PMN) were labeled with calcein AM for 10 min, incubated with [Hyp3]-bradykinin (BK) (0.1–100 µM) for 30 min, or buffer as control, and then were placed into the upper wells of modified Boyden chambers. Assessment of chemotaxis toward IL-8 (A) or nondirectional movement to buffer (B) was determined by measuring the amount of fluorescence in the lower wells as described in Materials and Methods. A is a representative graph of one of four experiments performed all with similar results.

 
Inhibition of ACE decreases LPS-induced expression of PAI-1 in the lung

We have recently shown that PAI-1 expression increases in the lung after exposure to aerosolized LPS and that PAI-1 regulates pulmonary neutrophil recruitment in our model of LPS-induced acute lung inflammation (31). As ACE has been shown to regulate PAI-1 expression (32, 33, 34, 35, 36, 37, 38, 39), we examined whether systemic inhibition of ACE decreased PAI-1 expression in the lung after LPS exposure. Pretreatment of mice with enalapril (10 mg/kg) for 6 days decreased the LPS-induced up-regulation of total PAI-1 in the lung and alveolar compartment, and levels of active PAI-1 in the lung, compared with LPS exposure alone (Fig. 5).


Figure 5
View larger version (10K):
[in this window]
[in a new window]

  		FIGURE 5. Pulmonary PAI-1 levels after exposure to LPS are diminished with enalapril pretreatment. Levels of total PAI-1 in lung (A) or BALF (B) or active PAI-1 in the lung (C) were determined by ELISA from animals pretreated with enalapril only (E), pretreated with enalapril and exposed to LPS (L+E), exposed to LPS alone (L), or left unmanipulated (C). *, p < 0.01 L vs L+E; #, p < 0.001 L vs L+E.

 
Administration of PAI-1 reverses the inhibitory effect of systemic ACE inhibition on the recruitment of neutrophils to the lung after exposure to LPS

As LPS-induced PAI-1 levels in the lung were decreased with enalapril pretreatment, we further examined the role of PAI-1 in regulating neutrophil recruitment to the alveolar space in the setting of systemic ACE inhibition. C57BL/6 mice were pretreated with enalapril (10 mg/kg, 6 days), then administered constitutively active PAI-1 (10 or 50 µg/mouse), or saline as control, 1 h before LPS exposure. The intratracheal administration of PAI-1 dose dependently reversed the inhibitory effect of enalapril on neutrophil recruitment to the alveolar compartment after LPS exposure (Fig. 6).


Figure 6
View larger version (12K):
[in this window]
[in a new window]

  		FIGURE 6. PAI-1 reverses the inhibitory effect of enalapril on LPS-induced pulmonary neutrophil recruitment. Recombinant constitutively active PAI-1 (10 or 50 µg/mouse), or PBS, was administered intratracheally to C57BL/6 mice (n = 5), pretreated with enalapril (10 mg/kg; 6 days), 1 h before exposure to LPS. Four hours after LPS exposure recruitment of neutrophils to the alveolar space was assessed as described above. *, p < 0.001 LPS vs LPS plus enalapril; #, p < 0.01 LPS plus enalapril plus PAI-1 (10 ) vs LPS plus enalapril; **, p < 0.001 LPS plus enalapril plus PAI-1 (50 ) vs LPS plus enalapril.

 
Inhibition of ATII-mediated signaling decreases pulmonary PAI-1 levels in LPS-exposed lungs

As administration of bradykinin agonists significantly inhibited LPS-induced pulmonary neutrophil recruitment, this suggested that bradykinin mediated signaling may also regulate pulmonary PAI-1 levels after exposure to LPS. No difference in LPS-induced PAI-1 levels, however, were found in mice pretreated with the bradykinin receptor agonists and exposed to LPS compared with those exposed to LPS alone (Fig. 7A). As ATII has been shown to up-regulate PAI-1 expression (40, 41, 42, 43, 44, 45, 46, 47), we next examined whether ATII-induced signaling regulates PAI-1 expression after LPS exposure in our model. To examine this possibility, mice were pretreated with losartan (10 mg/kg) for 3 days and then exposed to LPS. As can be seen in Fig. 7B, pretreatment with losartan significantly decreased PAI-1 levels in the lung and alveolar compartment after exposure to LPS. To confirm these results, mice deficient in the ATII type 1a receptor, or wild-type controls, were exposed to LPS with pulmonary PAI-1 levels assessed. Similar to our results using the ATII 1a receptor antagonist losartan, a deficiency in ATII 1a receptor expression was associated with a decrease in pulmonary PAI-1 expression after LPS exposure (Fig. 7C).


Figure 7
View larger version (18K):
[in this window]
[in a new window]

  		FIGURE 7. Inhibition of ATII-induced signaling, but not bradykinin-mediated signaling, diminishes the LPS-induced increase in PAI-1 levels. A, Mice (C57BL/6) (n = 5) were administered the bradykinin B1 receptor agonist [Lys-des-Arg9]-bradykinin (100 µg/kg, i.v.) (B1), the bradykinin B2 receptor agonist [Hyp3]-bradykinin (100 µg/kg, i.v.) (B2), or PBS as control, 1 h before exposure to LPS. Levels of total PAI-1 were then measured in the lung or BALF by ELISA. B, C57BL/6 mice (n = 5) were pretreated with losartan (10 mg/kg; orally), or hydroxymethylpropylcellulose as control, for 3 days and then exposed to aerosolized LPS. Total PAI-1 levels 4 h after LPS exposure in lung (left) and BALF (right) were assessed by ELISA. *, p < 0.05 LPS plus losartan vs LPS. C, Mice deficient in the type 1a ATII receptor (ATII 1aR–/–) or wild-type controls (WT) were exposed to LPS with total PAI-1 levels from lung (left) and BALF (right) measured 4 h after exposure to LPS. *, p < 0.01 WT vs AT1aR–/–.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
A role for ACE has been well established in the underlying pathophysiology of cardiovascular disease. Overexpression of ACE increases disease risk and worsens outcomes, whereas inhibition of ACE decreases the incidence of coronary artery disease and improves outcomes in congestive heart failure (1, 2, 3, 4, 5, 6). Several studies have additionally implicated a role for ACE in pulmonary disease. Evidence supporting such a role for ACE includes the increased ACE levels in BALF from subjects with interstitial lung disease, sarcoidosis, pneumonia, and ARDS (7, 8); the increased incidence of pneumonia and ARDS in subjects with the ACE overexpressing polymorphism (9, 51); and the positive correlation between BALF ACE levels and clinical outcomes in ARDS (9). Although these studies strongly suggest a role for ACE in pulmonary disease, and in particular ARDS, the role of ACE in specific etiologies known to induce ARDS and the mechanisms by which ACE regulates the acute inflammatory response in the lung is poorly understood.

Our results presented here suggest that ACE regulates neutrophil recruitment to the lung after exposure to LPS, an early feature of the pathogenesis of ARDS. Although modulation of the RAS has been shown to decrease neutrophil influx to the lung after exposure to bacterial organisms or formylated bacterial peptides (21, 22), a role for ACE in regulating acute lung inflammation after exposure to LPS has not previously been examined. In addition, the decrease in LPS-induced pulmonary neutrophil recruitment in our study was not due to alterations in hemodynamics because pretreatment with the antihypertensive agent hydralazine had no effect on neutrophil accumulation in the lung after exposure to LPS, even though pretreatment with hydralazine decreased mean arterial blood pressure to a similar extent compared with pretreatment with enalapril (Fig. 1, C and D).

As ACE regulates levels of both angiotensin II and bradykinin, a decrease in ATII and/or an increase in bradykinin-induced signaling may be mechanisms for the diminution in pulmonary neutrophil recruitment in the setting of systemic ACE inhibition in our study. We propose that both an increase in bradykinin and a decrease in ATII-induced signaling are mechanisms regulating the decrease in pulmonary neutrophil recruitment in our model. In support for a role of bradykinin-induced signaling is that administration of bradykinin receptor agonists diminished neutrophil influx to the lung after exposure to LPS (Fig. 2A). Furthermore, pretreatment with antagonists to the bradykinin receptors reversed the inhibitory effect of systemic ACE inhibition, thereby implicating an increase in bradykinin-mediated signaling as a mechanism for the decrease in pulmonary neutrophil accumulation with enalapril pretreatment. Although not as robust, blockade of ATII signaling, via the ATII 1a receptor antagonist losartan, also diminished neutrophil recruitment to the lung, thereby suggesting that an enalapril mediated decrease in ATII-induced signaling is an additional mechanism for the diminution in pulmonary neutrophil recruitment in our model, particularly at later time points. Other groups have also reported roles for ATII and bradykinin in regulating neutrophil recruitment to the lung. Antagonism of the ATII 1a receptor decreased cellular lung inflammation in a model of bleomycin-induced interstitial lung disease and neutrophil recruitment after intratracheal administration of fMLP, Pseudomonas aeruginosa, and Bordetella bronchiseptica (20, 21, 22). In contrast to ATII mediated signaling, the role of bradykinin in pulmonary neutrophil recruitment appears to be agonist specific. Blockade of the bradykinin B2 receptor increased pulmonary neutrophil accumulation in both allergic and immune complex mediated models of lung inflammation, suggesting an anti-inflammatory role for bradykinin, similar to our results presented here (Fig. 2B) (27, 29). In contrast, antagonism of the B2 receptor decreased neutrophil recruitment to the lung in models of ischemia-reperfusion, acute lung inflammation induced by i.v. Sephadex bead administration, and in a sepsis model of acute lung injury (30, 52, 53), and blockade of the B1 receptor decreased neutrophil influx induced by the localized administration of IL-1β (54).

Although bradykinin-induced signaling has been suggested to regulate neutrophil recruitment in acute inflammation, the mechanism by which bradykinin mediates these effects is at present unknown. Bradykinin, as well as ATII, are known to induce the release of neutrophil chemoattractants from endothelial cells and alveolar macrophages (55, 56, 57, 58, 59). As we found, however, no change in the levels of the neutrophil chemoattractants KC or MIP-2 in BALF from mice pretreated with enalapril and exposed to LPS compared with those exposed to LPS alone; a decrease in the neutrophil chemoattractant gradient in the lung is an unlikely mechanism for the inhibition of pulmonary neutrophil accumulation in the setting of systemic ACE inhibition. Our findings do suggest that bradykinin-induced signaling inhibits neutrophil chemotaxis toward a chemoattractant gradient. A previous study has suggested that bradykinin induces neutrophil chemotaxis (60); however, our findings presented here are in contrast to that previous study. Whereas we found no induction of chemotaxis with bradykinin alone (data not shown), pre-exposure of neutrophils to bradykinin decreased the subsequent chemotaxis to IL-8 without effecting the nondirectional movement of neutrophils (Fig. 4). To our knowledge this is the first description that bradykinin regulates neutrophil chemotaxis to known neutrophil chemoattractants. Although beyond the scope of the present study, the mechanisms by which bradykinin regulates neutrophil chemotaxis is not known but is the focus of ongoing studies.

Bradykinin is also known to up-regulate expression of NO, with inhibition of inducible NO expression reported to increase pulmonary neutrophil recruitment in other model systems (61, 62, 63). The possibility exists that ACE inhibition, or the administration of bradykinin receptor agonists, to LPS-exposed mice augmented levels of NO resulting in a decrease in neutrophil recruitment to the lung. Studies are currently underway to examine this possibility. Finally, ACE inhibitors have been shown recently to directly bind bradykinin receptors in vitro, thereby augmenting bradykinin-mediated signaling (64). Although a similar effect has not been shown in vivo, the possibility exists that enalapril binding to bradykinin receptors in the lung or on the neutrophil cell surface may have been a mechanism for the decrease in neutrophil accumulation to the lung after exposure to LPS in our study. Both the reversal of the effect of enalapril pretreatment by the bradykinin receptor antagonists and the more robust inhibition of pulmonary neutrophil recruitment with enalapril pretreatment, compared with pretreatment with the bradykinin receptor agonists alone, support such a mechanism. Although not the focus of the current study, such a process would provide a novel mechanism for the role of ACE inhibitors in regulating acute lung inflammation in vivo.

Similarly for ATII, the mechanisms by which ATII regulates neutrophil recruitment to areas of acute inflammation is poorly understood. Inhibition of ATII has been shown to decrease neutrophil capillary retention and adhesion through diminishing the expression of L-selectin and Cd11b (17, 18). Although heretofore unexplored in acute pulmonary inflammation, and not explored herein, a decrease in L-selectin or the expression of Cd11b may be mechanisms by which inhibition of ATII-induced signaling decreased LPS-induced neutrophil recruitment to the lung in our model. We do propose, however, that a decrease in PAI-1 expression, via a decrease in ATII-mediated signaling, is a mechanism for the diminution in LPS-induced neutrophil recruitment in the setting of systemic ACE inhibition. Expression of PAI-1 is dependent on the RAS. Inhibition of ACE decreases PAI-1 levels in human subjects with hypertension or the acute coronary syndrome and limits PAI-1 expression in vitro (32, 33, 34, 35, 36, 37, 38, 39). This effect of ACE inhibition on PAI-1 expression likely occurs via a decrease in ATII levels, as ATII 1a receptor antagonists decrease serum PAI-1 levels in human subjects and in cell cultures in vitro and the administration of ATII up-regulates PAI-1 expression, both in vivo and in in vitro models (40, 41, 42, 43, 44, 45, 46, 47). Although inhibition of the RAS has been shown to decrease PAI-1 levels in cardiovascular disease, which was associated with improved outcomes, no study to date has investigated a role of the RAS in pulmonary PAI-1 expression (32, 33, 34, 39, 65). In addition, and more specifically, no study to our knowledge has examined the potential role of the RAS in regulating pulmonary PAI-1 expression after exposure to LPS and the role of RAS mediated PAI-1 expression in regulating LPS-induced pulmonary neutrophil recruitment. Our findings presented herein suggest that ACE is one factor that regulates the LPS-induced increase in pulmonary PAI-1 levels, as PAI-1 levels in the lung after exposure to LPS were diminished with systemic ACE inhibition. In addition, our results suggest that ATII-induced signaling regulates LPS-induced pulmonary PAI-1 expression as PAI-1 levels after LPS exposure were decreased both in animals pretreated with losartan and in ATII 1a receptor-deficient mice. In contrast, pulmonary PAI-1 expression after exposure to LPS does not appear to be regulated through bradykinin, as administration of bradykinin receptor antagonists to enalapril pretreated mice or pretreatment with bradykinin agonists alone did not alter PAI-l levels after LPS exposure (Fig. 6A and data not shown). An overview of the proposed mechanisms for the regulation of LPS-induced pulmonary neutrophil recruitment by ATII and bradykinin is shown in Fig. 8.


Figure 8
View larger version (12K):
[in this window]
[in a new window]

  		FIGURE 8. Schematic of proposed mechanisms for the regulation of LPS-induced pulmonary neutrophil recruitment by bradykinin and ATII. Exposure to LPS increases pulmonary levels of IL-8 and PAI-1, both of which induce neutrophil recruitment to the lung. ACE inhibitors (ACE-I) decrease the conversion of angiotensin I (ATI) to ATII, which is proposed to diminish pulmonary PAI-1 expression, and ACE-I increase levels of bradykinin, which is proposed to limit neutrophil chemotaxis to IL-8.

 
We have recently shown that the mitogen-activating kinase JNK regulates LPS-induced pulmonary PAI-1 expression and that PAI-1 regulates the recruitment of neutrophils to the lung after exposure to LPS (31). Our current study now extends those findings and suggests that ACE activity, likely through ATII, is an additional pathway regulating PAI-1 expression in the lung after exposure to LPS and furthermore that a decrease in PAI-1 expression is a mechanism for the diminution in pulmonary neutrophil recruitment with ACE inhibition, as administration of exogenous PAI-1 reversed the inhibitory effect of enalapril on neutrophil influx to the lung after exposure to LPS (Fig. 5). Finally, our results suggest that ATII mediated signaling may regulate the activation of JNK in the lung after exposure to LPS.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by Grants HL-68743, HL-67179, and HL-61407 from the National Institutes of Health. Back

2 Address correspondence and reprint requests to Dr. Patrick G. Arndt, Division of Pulmonary and Critical Care Medicine, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Denver, CO 80206. E-mail address: arndt108{at}umn.edu Back

3 Abbreviations used in this paper: RAS, renin angiotensin system; ACE, angiotensin-converting enzyme; ARDS, acute respiratory distress syndrome; ATII, angiotensin II; BALF, bronchoalveolar lavage fluid; KRP-D, Kreb’s Ringers phosphate with dextrose; MPO, myeloperoxidase; PAI-1, plasminogen activator inhibitor-1. Back

Received for publication February 21, 2006. Accepted for publication August 30, 2006.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Pfeffer, M. A., E. Braunwald, L. A. Moye, L. Basta, E. J. Brown, Jr, T. E. Cuddy, B. R. Davis, E. M. Geltman, S. Goldman, G. C. Flaker, et al 1992. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. 327: 669-677. [Abstract]
  2. Yusuf, S., C. J. Pepine, C. Garces, H. Pouleur, D. Salem, J. Kostis, C. Benedict, M. Rousseau, M. Bourassa, B. Pitt. 1992. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 340: 1173-1178. [Medline]
  3. Schunkert, H., H. W. Hense, S. R. Holmer, M. Stender, S. Perz, U. Keil, B. H. Lorell, G. A. Riegger. 1994. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N. Engl. J. Med. 330: 1634-1638. [Abstract/Free Full Text]
  4. Cambien, F., O. Poirier, L. Lecerf, A. Evans, J. P. Cambou, D. Arveiler, G. Luc, J. M. Bard, L. Bara, S. Ricard, et al 1992. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359: 641-644. [Medline]
  5. Dickstein, K., J. Kjekshus. 1999. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am. J. Cardiol. 83: 477-481. [Medline]
  6. Moller, J. E., U. Dahlstrom, O. Gotzsche, A. Lahiri, K. Skagen, G. S. Andersen, K. Egstrup. 2004. Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic substudy. Am. Heart J. 147: 494-501. [Medline]
  7. Specks, U., W. J. Martin, II, M. S. Rohrbach. 1990. Bronchoalveolar lavage fluid angiotensin-converting enzyme in interstitial lung diseases. Am. Rev. Respir. Dis. 141: 117-123. [Medline]
  8. Idell, S., F. Kueppers, M. Lippmann, H. Rosen, M. Niederman, A. Fein. 1987. Angiotensin converting enzyme in bronchoalveolar lavage in ARDS. Chest 91: 525-526.
  9. Marshall, R. P., S. Webb, G. J. Bellingan, H. E. Montgomery, B. Chaudhari, R. J. McAnulty, S. E. Humphries, M. R. Hill, G. J. Laurent. 2002. Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 166: 646-650. [Abstract/Free Full Text]
  10. Sekizawa, K., T. Matsui, T. Nakagawa, K. Nakayama, H. Sasaki. 1998. ACE inhibitors and pneumonia. Lancet 352: 1069[Medline]
  11. Okaishi, K., S. Morimoto, K. Fukuo, T. Niinobu, S. Hata, T. Onishi, T. Ogihara. 1999. Reduction of risk of pneumonia associated with use of angiotensin I converting enzyme inhibitors in elderly inpatients. Am. J. Hypertens. 12: 778-783. [Medline]
  12. Ohkubo, T., N. Chapman, B. Neal, M. Woodward, T. Omae, J. Chalmers. 2004. Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. Am. J. Respir. Crit. Care Med. 169: 1041-1045. [Abstract/Free Full Text]
  13. Araki, M., T. Kanda, S. Imai, T. Suzuki, K. Murata, I. Kobayashi. 1995. Comparative effects of losartan, captopril, and enalapril on murine acute myocarditis due to encephalomyocarditis virus. J. Cardiovasc. Pharmacol. 26: 61-65. [Medline]
  14. Rezkalla, S., R. A. Kloner, G. Khatib, R. Khatib. 1990. Beneficial effects of captopril in acute coxsackievirus B3 murine myocarditis. Circulation 81: 1039-1046. [Abstract/Free Full Text]
  15. Godsel, L. M., J. S. Leon, K. Wang, J. L. Fornek, A. Molteni, D. M. Engman. 2003. Captopril prevents experimental autoimmune myocarditis. J. Immunol. 171: 346-352. [Abstract/Free Full Text]
  16. Kupatt, C., H. Habazettl, S. Zahler, C. Weber, B. F. Becker, K. Messmer, E. Gerlach. 1997. ACE-inhibition prevents postischemic coronary leukocyte adhesion and leukocyte-dependent reperfusion injury. Cardiovasc. Res. 36: 386-395. [Abstract/Free Full Text]
  17. Riaz, A. A., Y. Wang, R. Schramm, T. Sato, M. D. Menger, B. Jeppsson, H. Thorlacius. 2004. Role of angiotensin II in ischemia/reperfusion-induced leukocyte-endothelium interactions in the colon. FASEB J. 18: 881-883. [Abstract/Free Full Text]
  18. Ito, H., K. Takemori, T. Suzuki. 2001. Role of angiotensin II type 1 receptor in the leucocytes and endothelial cells of brain microvessels in the pathogenesis of hypertensive cerebral injury. J. Hypertens. 19: 591-597. [Medline]
  19. Bregonzio, C., I. Armando, H. Ando, M. Jezova, G. Baiardi, J. M. Saavedra. 2003. Anti-inflammatory effects of angiotensin II AT1 receptor antagonism prevent stress-induced gastric injury. Am. J. Physiol. 285: G414-G423.
  20. Li, X., H. Rayford, B. D. Uhal. 2003. Essential roles for angiotensin receptor AT1a in bleomycin-induced apoptosis and lung fibrosis in mice. Am. J. Pathol. 163: 2523-2530. [Abstract/Free Full Text]
  21. Raiden, S., Y. Pereyra, V. Nahmod, C. Alvarez, L. Castello, M. Giordano, J. Geffner. 2000. Losartan, a selective inhibitor of subtype AT1 receptors for angiotensin II, inhibits neutrophil recruitment in the lung triggered by fMLP. J. Leukocyte Biol. 68: 700-706. [Abstract/Free Full Text]
  22. Raiden, S., K. Nahmod, V. Nahmod, G. Semeniuk, Y. Pereira, C. Alvarez, M. Giordano, J. R. Geffner. 2002. Nonpeptide antagonists of AT1 receptor for angiotensin II delay the onset of acute respiratory distress syndrome. J. Pharmacol. Exp. Ther. 303: 45-51. [Abstract/Free Full Text]
  23. Rinaldo, J. E., J. H. Dauber. 1985. Modulation of endotoxin-induced neutrophil alveolitis by captopril and by hyperoxia. J. Leukocyte Biol. 37: 87-99. [Abstract]
  24. Cookson, W. O., M. S. Wiseman, D. J. Shale. 1985. Angiotensin converting enzyme and endotoxin induced lung damage in the mouse. Thorax 40: 774-777. [Abstract/Free Full Text]
  25. Abraham, W. M., R. M. Burch, S. G. Farmer, M. W. Sielczak, A. Ahmed, A. Cortes. 1991. A bradykinin antagonist modifies allergen-induced mediator release and late bronchial responses in sheep. Am. Rev. Respir. Dis. 143: 787-796. [Medline]
  26. Eric, J., B. H. Gabra, P. Sirois. 2003. Implication of the bradykinin receptors in antigen-induced pulmonary inflammation in mice. Br. J. Pharmacol. 138: 1589-1597. [Medline]
  27. Gama Landgraf, R., P. Sirois, S. Jancar. 2003. Differential modulation of murine lung inflammation by bradykinin B1 and B2 selective receptor antagonists. Eur. J. Pharmacol. 460: 75-83. [Medline]
  28. Bandeira-Melo, C., A. S. Calheiros, P. M. Silva, R. S. Cordeiro, M. M. Teixeira, M. A. Martins. 1999. Suppressive effect of distinct bradykinin B2 receptor antagonist on allergen-evoked exudation and leukocyte infiltration in sensitized rats. Br. J. Pharmacol. 127: 315-320. [Medline]
  29. Gama Landgraf, R., S. Jancar, A. A. Steil, P. Sirois. 2004. Modulation of allergic and immune complex-induced lung inflammation by bradykinin receptor antagonists. Inflamm. Res. 53: 78-83. [Medline]
  30. Perron, M. S., F. Gobeil, Jr, S. Pelletier, D. Regoli, P. Sirois. 1999. Involvement of bradykinin B1 and B2 receptors in pulmonary leukocyte accumulation induced by Sephadex beads in guinea pigs. Eur. J. Pharmacol. 376: 83-89. [Medline]
  31. Arndt, P. G., S. K. Young, G. S. Worthen. 2005. Regulation of lipopolysaccharide-induced lung inflammation by plasminogen activator inhibitor-1 through a JNK-mediated pathway. J. Immunol. 175: 4049-4059. [Abstract/Free Full Text]
  32. Wagner, A., H. Herkner, W. Schreiber, A. Bur, C. Woisetschlager, G. Stix, A. N. Laggner, M. M. Hirschl. 2002. Ramipril prior to thrombolysis attenuates the early increase of PAI-1 in patients with acute myocardial infarction. Thromb. Haemost. 88: 180-185. [Medline]
  33. Hirschl, M. M., A. Wagner, M. Gwechenberger, H. Herkner, M. Mullner, C. Woisetschlager, A. N. Laggner. 1998. Attenuation of thrombolysis-induced increase of plasminogen activator inhibitor-1 by intravenous enalaprilat. Thromb. Haemost. 79: 140-143. [Medline]
  34. Brown, N. J., M. Agirbasli, D. E. Vaughan. 1999. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 34: 285-290. [Abstract/Free Full Text]
  35. Nagata, K., T. Ishibashi, T. Sakamoto, K. Nakazato, Y. Seino, K. Yokoyama, H. Ohkawara, T. Teramoto, Y. Maruyama. 2001. Effects of blockade of the renin-angiotensin system on tissue factor and plasminogen activator inhibitor-1 synthesis in human cultured monocytes. J. Hypertens. 19: 775-783. [Medline]
  36. Fogari, R., A. Mugellini, A. Zoppi, L. Corradi, P. Preti, P. Lazzari, G. Derosa. 2002. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am. J. Hypertens. 15: 316-320. [Medline]
  37. Brown, N. J., M. A. Agirbasli, G. H. Williams, W. R. Litchfield, D. E. Vaughan. 1998. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 32: 965-971. [Abstract/Free Full Text]
  38. Brown, N. J., S. Kumar, C. A. Painter, D. E. Vaughan. 2002. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time. Hypertension 40: 859-865. [Abstract/Free Full Text]
  39. Pahor, M., L. V. Franse, S. R. Deitcher, W. C. Cushman, K. C. Johnson, R. I. Shorr, K. Kottke-Marchant, R. P. Tracy, G. W. Somes, W. B. Applegate. 2002. Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation 105: 457-461. [Abstract/Free Full Text]
  40. Vaughan, D. E., S. A. Lazos, K. Tong. 1995. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J. Clin. Invest. 95: 995-1001. [Medline]
  41. Nishimura, H., H. Tsuji, H. Masuda, T. Kasahara, M. Yoshizumi, T. Sugano, S. Kimura, H. Kawano, Y. Kunieda, S. Yano, et al 1999. The effects of angiotensin metabolites on the regulation of coagulation and fibrinolysis in cultured rat aortic endothelial cells. Thromb. Haemost. 82: 1516-1521. [Medline]
  42. van Leeuwen, R. T., A. Kol, F. Andreotti, C. Kluft, A. Maseri, G. Sperti. 1994. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 90: 362-368. [Abstract/Free Full Text]
  43. Mehta, J. L., D. Y. Li, H. Yang, M. K. Raizada. 2002. Angiotensin II and IV stimulate expression and release of plasminogen activator inhibitor-1 in cultured human coronary artery endothelial cells. J. Cardiovasc. Pharmacol. 39: 789-794. [Medline]
  44. Erdem, Y., C. Usalan, I. C. Haznedaroglu, B. Altun, M. Arici, U. Yasavul, C. Turgan, S. Caglar. 1999. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am. J. Hypertens. 12: 1071-1076. [Medline]
  45. Feener, E. P., J. M. Northrup, L. P. Aiello, G. L. King. 1995. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J. Clin. Invest. 95: 1353-1362. [Medline]
  46. Ridker, P. M., C. L. Gaboury, P. R. Conlin, E. W. Seely, G. H. Williams, D. E. Vaughan. 1993. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 87: 1969-1973. [Abstract/Free Full Text]
  47. Nakamura, S., I. Nakamura, L. Ma, D. E. Vaughan, A. B. Fogo. 2000. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int. 58: 251-259. [Medline]
  48. Arndt, P. G., S. K. Young, J. G. Lieber, M. B. Fessler, J. A. Nick, G. S. Worthen. 2005. Inhibition of c-Jun N-terminal kinase limits lipopolysaccharide-induced pulmonary neutrophil influx. Am. J. Respir. Crit. Care Med. 171: 978-986. [Abstract/Free Full Text]
  49. Fessler, M. B., S. K. Young, S. Jeyaseelan, J. G. Lieber, P. G. Arndt, J. A. Nick, G. S. Worthen. 2005. A role for hydroxy-methylglutaryl coenzyme a reductase in pulmonary inflammation and host defense. Am. J. Respir. Crit. Care Med. 171: 606-615. [Abstract/Free Full Text]
  50. Nick, J. A., S. K. Young, P. G. Arndt, J. G. Lieber, B. T. Suratt, K. R. Poch, N. J. Avdi, K. C. Malcolm, C. Taube, P. M. Henson, G. S. Worthen. 2002. Selective suppression of neutrophil accumulation in ongoing pulmonary inflammation by systemic inhibition of p38 mitogen-activated protein kinase. J. Immunol. 169: 5260-5269. [Abstract/Free Full Text]
  51. Morimoto, S., K. Okaishi, M. Onishi, T. Katsuya, J. Yang, M. Okuro, S. Sakurai, T. Onishi, T. Ogihara. 2002. Deletion allele of the angiotensin-converting enzyme gene as a risk factor for pneumonia in elderly patients. Am. J. Med. 112: 89-94. [Medline]
  52. Souza, D. G., V. Pinho, J. L. Pesquero, E. S. Lomez, S. Poole, L. Juliano, A. Correa, Jr, M. S. de A. Castro, M. M. Teixeira. 2003. Role of the bradykinin B2 receptor for the local and systemic inflammatory response that follows severe reperfusion injury. Br. J. Pharmacol. 139: 129-139. [Medline]
  53. Ridings, P. C., C. R. Blocher, B. J. Fisher, A. A. Fowler, III, H. J. Sugerman. 1995. Beneficial effects of a bradykinin antagonist in a model of gram-negative sepsis. J. Trauma 39: 81-88. [Medline]
  54. Ahluwalia, A., M. Perretti. 1996. Involvement of bradykinin B1 receptors in the polymorphonuclear leukocyte accumulation induced by IL-1β in vivo in the mouse. J. Immunol. 156: 269-274. [Abstract]
  55. Farber, H. W., D. M. Center, S. Rounds, S. M. Danilov. 1990. Components of the angiotensin system cause release of a neutrophil chemoattractant from cultured bovine and human endothelial cells. Eur. Heart J. 11: (Suppl. B):100-107. [Abstract/Free Full Text]
  56. Koyama, S., E. Sato, H. Nomura, K. Kubo, M. Miura, T. Yamashita, S. Nagai, T. Izumi. 1998. Bradykinin stimulates type II alveolar cells to release neutrophil and monocyte chemotactic activity and inflammatory cytokines. Am. J. Pathol. 153: 1885-1893. [Abstract/Free Full Text]
  57. Pang, L., A. J. Knox. 1998. Bradykinin stimulates IL-8 production in cultured human airway smooth muscle cells: role of cyclooxygenase products. J. Immunol. 161: 2509-2515. [Abstract/Free Full Text]
  58. Hayashi, R., N. Yamashita, S. Matsui, M. Maruyama, E. Sugiyama, S. Sugiyama, M. Kobayashi. 1998. Bradykinin stimulates interleukin-8 production by human lung fibroblasts. Immunology 95: 507-511. [Medline]
  59. Sato, E., S. Koyama, H. Nomura, K. Kubo, M. Sekiguchi. 1996. Bradykinin stimulates alveolar macrophages to release neutrophil, monocyte, and eosinophil chemotactic activity. J. Immunol. 157: 3122-3129. [Abstract]
  60. Paegelow, I., S. Trzeczak, S. Bockmann, G. Vietinghoff. 2002. Migratory responses of polymorphonuclear leukocytes to kinin peptides. Pharmacology 66: 153-161. [Medline]
  61. Speyer, C. L., T. A. Neff, R. L. Warner, R. F. Guo, J. V. Sarma, N. C. Riedemann, M. E. Murphy, H. S. Murphy, P. A. Ward. 2003. Regulatory effects of iNOS on acute lung inflammatory responses in mice. Am. J. Pathol. 163: 2319-2328. [Abstract/Free Full Text]
  62. Hickey, M. J., K. A. Sharkey, E. G. Sihota, P. H. Reinhardt, J. D. Macmicking, C. Nathan, P. Kubes. 1997. Inducible nitric oxide synthase-deficient mice have enhanced leukocyte-endothelium interactions in endotoxemia. FASEB J. 11: 955-964. [Abstract]
  63. Roman, A., R. Legallo, E. D. McGahren. 2004. Blocking of endogenous nitric oxide increases white blood cell accumulation in rat lung. J. Pediatr. Surg. 39: 48-52. [Medline]
  64. Ignjatovic, T., F. Tan, V. Brovkovych, R. A. Skidgel, E. G. Erdos. 2002. Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of bradykinin B1 receptor. J. Biol. Chem. 277: 16847-16852. [Abstract/Free Full Text]
  65. Vaughan, D. E., J. L. Rouleau, P. M. Ridker, J. M. Arnold, F. J. Menapace, M. A. Pfeffer. 1997. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation 96: 442-447. [Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
G. B. Allen, M. E. Cloutier, Y. C. Larrabee, K. Tetenev, S. T. Smiley, and J. H. T. Bates
Neither fibrin nor plasminogen activator inhibitor-1 deficiency protects lung function in a mouse model of acute lung injury
Am J Physiol Lung Cell Mol Physiol, March 1, 2009; 296(3): L277 - L285.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. A. Richardson, A. Gupta, L. A. O'Brien, D. T. Berg, B. Gerlitz, S. Syed, G. R. Sharma, M. S. Cramer, J. G. Heuer, E. J. Galbreath, et al.
Treatment of Sepsis-Induced Acquired Protein C Deficiency Reverses Angiotensin-Converting Enzyme-2 Inhibition and Decreases Pulmonary Inflammatory Response
J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 17 - 26.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arndt, P. G.
Right arrow Articles by Worthen, G. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arndt, P. G.
Right arrow Articles by Worthen, G. S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS